Español
English
Français
Deutsch
Português
- Autore:
- Eduardo Anitua
- Gorka Orive
- Vaquerizo V
- Plasencia MÁ
- Arribas I
- Seijas R
Comparison of intra-articular injections of plasma rich in growth factors (PRGF-Endoret) versus Durolane hyaluronic acid in the treatment of patients with symptomatic osteoarthritis: a randomized controlled trial
Arthroscopy. 2013 Oct;29(10):1635-43. The purpose of this study was to compare the efficacy and safety in a randomized, clinical trial of 3 injections of PRGF-Endoret (BTI Biotechnology Institute, Vitoria, Spain) versus one single intra-articular injection of Durolane hyaluronic acid (HA) (Q-MED AB, Uppsala, Sweden) as a treatment for reducing symptoms in patients with knee osteoarthritis (OA).
- Autore:
- Eduardo Anitua
- Gorka Orive
- Sánchez M
- Fiz N
- Azofra J
- Usabiaga J
- Aduriz Recalde E
- Garcia Gutierrez A
- Albillos J
- Gárate R
- Aguirre JJ
A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis
Arthroscopy. 2012 Aug;28(8):1070-8. This multicenter, double-blind clinical trial evaluated and compared the efficacy and safety of PRGF-Endoret (BTI Biotechnology Institute, Vitoria-Gasteiz, Spain), an autologous biological therapy for regenerative purposes, versus hyaluronic acid (HA) as a short-term treatment for knee pain from osteoarthritis.
- Autore:
- López-Plandolit S
- Morales MC
- Freire V
- Grau AE
- Durán JA.
Efficacy of plasma rich in growth factors for the treatment of dry eye
Cornea. 2011 Dec;30(12):1312-7. To evaluate the efficacy of plasma rich in growth factors (PRGF) for the treatment of moderate/severe dry eye.
- Autore:
- Eduardo Anitua
- Gorka Orive
- Mikel Sánchez
- Rosa Sarabia
- Julian Sanz
- José Javier Aguirre
- Autore:
- López-Plandolit S
- Morales MC
- Freire V
- Etxebarría J
- Durán JA.
Plasma rich in growth factors as a therapeutic agent for persistent corneal epithelial defects
Cornea. 2010 Aug;29(8):843-8. To evaluate the efficacy of topically applied autologous plasma rich in growth factors (PRGF) as a treatment for persistent epithelial defects (PEDs) of the cornea.